GKIM
DGX icon

GW&K Investment Management’s Quest Diagnostics DGX Stock Holding History

GW&K Investment Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28K Buy
134
+29
+28% +$5.69K ﹤0.01% 720
2026
Q1 		$21K Buy
105
+3
+3% +$583 ﹤0.01% 757
2025
Q4 		$18K Buy
102
+8
+9% +$1.46K ﹤0.01% 763
2025
Q3 		$18K Sell
94
-34
-27% -$6.03K ﹤0.01% 765
2025
Q2 		$23K Buy
128
+51
+66% +$8.86K ﹤0.01% 679
2025
Q1 		$13K Hold
77
– – ﹤0.01% 738
2024
Q4 		$12K Buy
77
+3
+4% +$467 ﹤0.01% 729
2024
Q3 		$11K Buy
74
+40
+118% +$5.97K ﹤0.01% 750
2024
Q2 		$5K Buy
34
+29
+580% +$3.97K ﹤0.01% 826
2024
Q1 		$1K Buy
5
+2
+67% +$259 ﹤0.01% 889
2023
Q4 		$0 Buy
3
+1
+50% +$131 ﹤0.01% 933
2023
Q3 		$0 Sell
2
-4
-67% -$533 ﹤0.01% 916
2023
Q2 		$1K Buy
+6
New +$827 ﹤0.01% 862
2022
Q3 		– Sell
-14
Closed -$2K – 510
2022
Q2 		$2K Buy
14
+6
+75% +$818 ﹤0.01% 739
2022
Q1 		$1K Buy
+8
New +$1.11K ﹤0.01% 757

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

GW&K Investment Management's DGX Position: Q2 2026 in Review

GW&K Investment Management increased its Quest Diagnostics (DGX) stake by 28% in Q2 2026, buying an estimated $5.69K and bringing the position to 134 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #720.

GW&K Investment Management first reported a position in DGX in Q1 2022 and has held it in 15 quarters since. 1,111 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • GW&K Investment Management held 134 shares of Quest Diagnostics worth $28K as of Q2 2026.
  • GW&K Investment Management bought 29 Quest Diagnostics shares in Q2 2026, an estimated $5.69K.
  • Quest Diagnostics made up ﹤0.01% of GW&K Investment Management's portfolio in Q2 2026, its #720 holding.
  • GW&K Investment Management first reported a position in Quest Diagnostics in Q1 2022 and has held it in 15 quarters since.
  • 1,111 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.